This mode of action has the potential to prevent tumor resistance and enhance treatment outcomes [58, 59], making clioquinol a promising alternative to traditional small-molecule VEGFR2 kinase inhibitors, such as lenvatinib and tivozanib. The gene discussed is KDR; the disease is neoplasm.